T 1777/21 (GLP-1 peptide dosing/NOVO NORDISK) of 05.12.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T177721.20231205
- Date of decision
- 5 December 2023
- Case number
- T 1777/21
- Online on
- 14 March 2024
- Petition for review of
- -
- Application number
- 14721834.1
- IPC class
- A61K 38/26A61P 3/10
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Oral dosing of GLP-1 compounds
- Applicant name
- Novo Nordisk A/S
- Opponent name
- Teva Pharmaceutical Industries Ltd.
Sanofi
Hexal AG
Galenicum Health S.L.U.
Lederer & Keller Patentanwälte Partnerschaft mbB
Generics (U.K.) Limited - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56
- Keywords
- Inventive step - (no)
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.